What Researchers Did
This review critically discussed the limited clinical benefits of hyperbaric oxygen (HBO) and misonidazole (MISO) as chemical modifiers of radiosensitivity.
What They Found
The review found that reoxygenation is a major factor limiting clinical gains from HBO and MISO. Other reasons included HBO's vasoconstrictive self-limitation and MISO's neurotoxicity, which prevented adequate radiosensitization. Newer clinical sensitizers like Ro-03-8799 and SR-2508 are expected to be 3 to 10 times more efficient than MISO.
What This Means for Canadian Patients
This review suggests that while some older radiosensitizers had limited success, the ongoing development of more effective agents could improve radiotherapy outcomes for Canadian patients with certain tumors. Identifying tumors with significant hypoxic cells could lead to more targeted and effective treatments.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
As a review from 1985, its findings are based on data and technologies available at that time, which may not reflect current advancements in radiosensitization.